$WASH

Stocks making big moves yesterday: Washington Trust Bancorp, Doximity, Myriad Genetics, Arhaus, and Gartner

Washington Trust Bancorp (WASH) rose 5% after beating Q3 2026 estimates. Doximity (DOCS) gained 7.3% following a partnership with Wolters Kluwer. Myriad Genetics (MYGN) surged 22.2% after selling its Prenatal Health unit to Labcorp. Arhaus (ARHS) climbed 6.5% on an upgrade and price target raise. Gartner (IT) increased 4.5% after price target hikes.

Original reporting
Published Oct 21, 2026, 7:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 7:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Stocks making big moves yesterday: Washington Trust Bancorp, Doximity, Myriad Genetics, Arhaus, and Gartner — source image
Decision brief

The 30-second read

$WASHBullishLow
01

Why it matters

Each listed company experienced a notable price move driven by fresh earnings, partnerships, divestitures, or analyst upgrades.

02

Market read

The roundup signals short‑term bullish opportunities across diverse sectors, useful for traders seeking momentum plays.

03

What to watch

Potential execution risk on Myriad's divestiture and the sustainability of Doximity's partnership benefits.

Relevance 4/10Novelty 4/10Timing: yesterday's moves, relevant for today’s trading

Background

The article is a daily roundup highlighting stocks that moved significantly after specific corporate events.

Company-level read

Ticker impact

$WASHBullishHigh confidence
Context

Washington Trust Bancorp rose 5% after reporting Q3 2026 results that beat sales and earnings expectations.

Expected impact

likely pressure to the upside as the market digests the earnings beat.

Evidence & confidence

Earnings beat typically supports further price gains in the short term.

$DOCSBullishHigh confidence
Context

Doximity jumped 7.3% after announcing a partnership with Wolters Kluwer Health to integrate UpToDate content.

Expected impact

upward pressure as the partnership may expand user engagement and revenue.

Evidence & confidence

Partnerships that add valuable content are viewed as growth catalysts.

$MYGNBullishHigh confidence
Context

Myriad Genetics surged 22.2% after agreeing to sell its Prenatal Health testing business to Labcorp for $210 million cash plus inventory.

Expected impact

strong upside as the cash proceeds improve balance sheet and focus on core assets.

Evidence & confidence

Large cash deals are typically well‑received by investors.

$ARHSBullishMedium confidence
Context

Arhaus climbed 6.5% after Piper Sandler upgraded it to Overweight and raised the price target to $13 from $9.

Expected impact

upward pressure as the new target suggests further upside.

Evidence & confidence

Upgrades often trigger short‑term buying.

$ITBullishMedium confidence
Context

Gartner rose 4.5% after Truist Securities and Wells Fargo raised their price targets following meetings at its IT Symposium.

Expected impact

moderate upside as analysts signal stronger outlook.

Evidence & confidence

Broker target hikes can sustain a rally.

Market effects

Positive sentiment spreads to regional banks, health‑tech, genetics, furniture retail, and advisory services sectors.

U.S. equities see modest broad‑based gains as multiple sectors receive upbeat news.

Limited to U.S. markets; no direct global macro impact.

Counterpoint

Some investors may view the rapid price spikes as over‑reactions and could consider short‑term profit taking.

Key entities

  • Washington Trust Bancorp

    Regional bank reporting strong Q3 results.

  • Doximity

    Medical professional network announcing a content partnership.

  • Myriad Genetics

    Genetic testing firm selling its prenatal business.

  • Arhaus

    Furniture retailer upgraded by Piper Sandler.

  • Gartner

    Research firm receiving broker target raises.

Related articles

$MYGNMedAI 8/10

Myriad Genetics presents data on cancer recurrence detection test

Myriad Genetics (NASDAQ:MYGN) presented data from the MONSTAR-SCREEN-3 study on its Precise MRD platform, showing it can detect molecular residual disease in colorectal and pancreatic cancer patients post-surgery, with early detection of recurrence. The study will be presented at the European Society for Medical Oncology Congress 2026. The company claims the platform offers personalized monitoring for recurrence risk.

$WASHMed

Washington Trust Bancorp Inc (WASH) (Q3 2026) Earnings Call Highlights: Net Income Climbs

Washington Trust Bancorp (WASH) reported Q3 2026 earnings with net income growth, but mortgage banking revenues fell 9% from Q2 and 10% year-over-year. Non-interest expenses are expected to rise by $1.5M in Q4, with an additional $750K charitable contribution. Loan growth may miss mid-single-digit targets, and competitive pressures are tightening spreads. The company has no plans for stock buybacks, focusing on loan growth instead.

$ARHSMed

Arhaus (ARHS) stock is up, what you need to know

Arhaus (ARHS) shares rose 2.5% after Piper Sandler upgraded the stock to Overweight and raised its price target to $13, citing improved comparable sales and margin recovery potential. The analyst expects sustainable EPS growth and limited disruption from new technology systems. The stock is trading near its 52-week high.